Panel – Re-evaluating our strategies for combination partnering
Immuno-Oncology Frontiers Europe
- How does BMS’s selection of a single preferential partner impact biotech and big pharma?
- What are the most effective partnering models in their eyes for combination development?
- If you are a biotech – should you seek to partner right up front? Or try to go it alone?